Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study.

Introduction A clear trend towards increased use of neoadjuvant therapy (NAT) compared to adjuvant therapy (AT) in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer has been observed in the past decade. 1 , 2 This trend reflects the similar survival benefit with either treatment st

also in 19,460 other papers